Negative in Ames, in vitro CHO chromosome aberration and rat bone marrow micronucleus assays
“Sunvozertinib was not mutagenic in an in vitro bacterial reverse mutation assay. Additionally, sunvozertinib did not cause chromosomal aberrations in an in vitro chromosome aberration assay in Chinese hamster ovary (CHO) cells. Sunvozertinib was not clastogenic in an in vivo bone marrow micronucleus test in rats”
✓ VerifiedFDA multi-discipline review, p. 34Source ↗
Carcinogenicity
Not conducted (advanced cancer indication, ICH S9)
“The Applicant did not conduct a carcinogenicity study with sunvozertinib; consistent with ICH S9, these studies are not warranted for the development of a drug intended for the treatment of patients with advanced cancer.”
✓ VerifiedFDA multi-discipline review, p. 34Source ↗
Reproductive & developmental
Rat and rabbit EFD: abortion, fetal death, reduced fetal weight, heart malformations and skeletal variations
“In the embryo-fetal development toxicity studies, sunvozertinib resulted in decreased body weight and abortion in pregnant rats and/or rabbits, dead fetuses, decreased fetal weight, heart malformations, increased supernumerary bone of fontanelle bone, and misaligned sternebra in fetus.”
✓ VerifiedFDA multi-discipline review, p. 70Source ↗
Safety pharmacology
hERG IC50 1.21 μM; no effects on respiratory, CNS or cardiovascular systems
“Sunvozertinib inhibited the function of hERG channel with an IC50 value of 1.21 μM. In addition, sunvozertinib showed no effect on respiratory system, CNS or cardiovascular system in the above studies, indicating that it has a favourable safety profile.”
✓ VerifiedFDA multi-discipline review, p. 44Source ↗
Not genotoxic overall: Ames negative; in vitro chromosome aberration positive without (not with) metabolic activation; rat micronucleus and comet negative